Status:

UNKNOWN

HMPL-813 in Treating Patients With Glioblastoma

Lead Sponsor:

Hutchison Medipharma Limited

Conditions:

Glioblastoma

Eligibility:

All Genders

18-100 years

Phase:

PHASE1

Brief Summary

This is an open-label study, to evaluated epitinib, which is a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), to treat glioblastoma patients with EGFR gene amplificat...

Detailed Description

Epitinib could cross BBB and show its efficacy in brain metastasis tumors. Patients with histologically confirmed glioblastoma; standard treatment failed or no standard treatment as well as EGFR gene ...

Eligibility Criteria

Inclusion

  • Histologically confirmed glioblastoma
  • Standard treatment failed or no standard treatment
  • EGFR gene amplification
  • Clearly measurable lesions (according to Response Assessment in Neuro-Oncolog (RANO))
  • Age ≥ 18
  • Eastern Cooperative Oncology Group (ECOG) score ≤2

Exclusion

  • Use of Antiepileptic drugs were used\] within 2 weeks before enrollment
  • Immunotherapy, anti-angiogenesis or EGFR TKI and its downstream pathway signaling molecules and other targeted drugs within 4 weeks before enrollment; temozolomide chemotherapy, cranial radiotherapy or other systemic anti-tumor therapy within 3 weeks before enrollment
  • Previous toxic effects of anticancer therapy have not yet been recovered (defined as not restored to 0 or 1 level, except alopecia) or have not been fully recovered from previous surgery
  • Uncontrolled active infections such as acute pneumonia, Hepatitis B Virus (HBV) and so on
  • Eye disease or dry eye syndrome history
  • Positive pregnancy tested result

Key Trial Info

Start Date :

January 26 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 31 2020

Estimated Enrollment :

29 Patients enrolled

Trial Details

Trial ID

NCT03231501

Start Date

January 26 2018

End Date

August 31 2020

Last Update

June 16 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Huashan Hospital

Shanghai, Shanghai Municipality, China, 200031

2

The second hospital affiliated to Zhejiang University Medical School

Hanzhou, Zhejiang, China, 310009